market perform
reason report
upgrad op valuat disconnect given diversifi biz
bottom line follow investor day increment
posit pipelin diversifi busi model
sale ou sale brand/otc abil deliv
roughli top-lin low-doubl digit ep compound-annual-growth-rate growth
time-frame well abil strengthen
balanc sheet debt/ebitda year-end despit
strength continu trade ev/ebitda
discount peer teva in-lin
compani endo thu upgrad
outperform rate market perform maintain
pt sever near-term catalyst believ
drive upsid includ regulatori approv
launch biosimilar neulasta us june gx advair
us june gx restasi juli biosimilar humira eu
revefenacin us nov new product launch
biosimilar herceptin us potenti late insulin
glargin eu revis ep vs
previous consensu expect see
multipl expans ev/ebitda investor get
comfort diversifi busi model differenti
durabl pipelin well strong balanc sheet
increment posit potenti advair
approv year manag indic earli march
posit meet fda applic believ
address fda outstand question applic
includ label question also note build inventori
readi launch day never possibl
full visibl fda approv decis believ base
manag comment applic high likelihood
approv estim ep contribut
driven fast ramp expect see mani
competitor near futur even delay
month continu see gener advair meaning contributor
continu next page
ev/ebitda multipl
net debt total capit
gener
compani inform leerink partner llc research
revenu
pleas refer page import disclosur price chart analyst certif
mylan biosimilars/complex product pipelin shape
one strongest industri
brand valu target pipelin complex product
complex oral solid dosag form insulin/
biosimilar program pipelin recent addit
includ humira eu botox aranesp toujeo perjeta
also showcas complex product pipelin first time
detail investor day includ restasi steril inject
invega sustenna risperd consta victoza sandostatin depo-
provera gx premarin believ found api sourc
meloxicam faster act version monthli gener copaxon
along dermatolog respiratori product
mylan diversifi busi model remain under-appreci
view believ investor under-appreci busi
diversif across geographi sale ou market
grow high singl digit product mix sale come
brand/otc product product concentr singl product
expect sale importantli mylan
gener busi outsid us experienc nearli
price headwind us even us expect mylan
gener busi grow mid-singl digit benefit
annual gener copaxon contribut along new
mylan strong balanc sheet well establish infrastructur
support earn expans longer term
project net debt ebitda
believ well way drive leverag close
well-round infrastructur
manufactur capabl presenc across countri
believ need make transform acquisit fill
signific gap enabl manag explor bolt-
acquisit time could potenti help drive oper
leverag longer term
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver could
expand multipl rel peer strong balanc sheet allow share
buy-back smaller bolt-on acquisit expand geograph and/or therapeut product area
despit divers natur busi stock continu trade
peer
last decad build busi across multipl area diversifi
busi point compani index outsid us
compris gener despit busi compos brand
counter over-the-counter last year continu trade peer group compani
three segment figur
figur ev/ebitda vs leerink compar index
look compar gener compani coverag figur
note trade compar ev/ebitda ratio endo trade
teva trade howev given diversif well
durabl busi believ deserv trade higher multipl rel
gener peer valuat assum multipl
outlin five key reason continu believ appropri multipl
key reason believ deserv trade multipl
sustain us gener busi uniqu pipelin asset drive
growth base estim us gener base busi sustain
mani peer expect base gener busi declin vs
declin teva declin endo larg dont see outsiz transit
product us gener portfolio expect declin meaning year
gener concerta teva also benefit annual gener
copaxon contribut addit believ scale pipelin
flexibl multipl dosag form includ difficult manufactur product result
durabl gener asset point gener advair investor day
maintain confid garner approv june target action date
underst signific contributor gener advair would given would
first ab-rat gener larg opportun entir class respiratori
product manufactur long struggl get gener approv addit
competit dynam play could gener market
mani month see benefit posit tailwind gener
advair see us gener busi grow significantli
better declin teva declin endo line
growth note driven two outsiz opportun believ
continu deliv asset market might level gener advair
would still differenti base formul detail interest program
investor day includ gener premarin symbicort victoza once-monthli version
copaxon assign valu product yet increment
encourag differenti gener portfolio well posit off-set
figur y/i chang us gx revenu across gener coverag
higher exposur ou cx/otc market expos neg
price effect us gener also meaning growth driver consolid
buy group continu drive meaning headwind across us gener compani
base busi encourag commentari believ
start see deceler eros nevertheless believ busi
well posit mitig impact us gener simpli heavili index
gener peer sale index us gener
roughli par teva significantli less
endo addit see meaning growth driver across compon
busi gener peer struggl match reiter high-singl digit growth
expect eu row region continu drive biosimilar launch
antiretrovir portfolio particular addit ou exposur consum cx
over-the-counter busi driven meda acquisit look drive forc growth go forward
compani look introduc mani product exist market establish new
foot market like china brazil cross-pollin product portfolio mani row
region typic seen brand exposur
comprehens biosimilar portfolio within gener coverag mylan
recogn early-on small molecul gener opportun start contract biosimilar
like key sourc growth go forward biosimilar program mylan
outlin product teva amneal biosimilar respect partnership
endo unlik make foray biosimilar space invest
biosimilar look well track start contribut year biosimilar neulasta could
approv june humira look pois enter eu market octob insulin glargin
appear readi eu launch come biosimilar pipelin contain mani usual
suspect herceptin avastin rituxan highlight biosimilar manufactur
also contain mani uniqu opportun biosimilar eylea botox novolog
wouldnt expect opportun ultim come market assign
conserv number product current late stage develop doesnt expect
meaning contribut biosimilar assum total compani
reiter expect doubl inject sale
growth biosimilar believ achiev
strong balanc sheet flexibl capit deploy believ balanc
sheet provid manag ampl flexibl either fill product offer
geograph and/or therapeut area level move toward share buy-back see mylan
leverag ratio meet manag goal compar
favor teva direct cash toward debt paydown endo
still litig payment issu see continu reduct mylan
leverag go forward therefor
see ampl flexibl grow over-the-counter busi via acquisit continu
continu top-lin bottom-lin compound-annual-growth-rate growth next year total
believ busi deliv compound-annual-growth-rate growth top line
ep revenu earn profil stand among gener coverag
compar valu includ partial year contribut
amneal
figur revenu ep compound-annual-growth-rate across gener coverag
chang model
gener copaxon mylan trx share hold steadi
rang manag state slightli lower expect still within rang
assumpt year assum exit share
upper lower gener copaxon revenu
gener advair follow manag commentari investor day continu believ
gener advair get approv june action date base commentari
gener advair filer sandoz hikma push back competit sandoz
competit hikma believ assumpt could conserv
end well see potenti upsid number delay occur
competitor rais gener advair revenu
reflect competitor delay
biosimilar humira partnership deal fujifilm kyowa kirin biolog biosimilar
humira confid abl come market eu market
format rais revenu contribut eu humira
oper expens lower sg spend spend
reflect oper effici busi base
manag high-level commentari spend
estim lower sale assum slight increas
us gener base busi eros howev off-set
reduct expens overal ep remain unchang
revenu total mostli unchang higher us gener revenu advair mostli off-set
lower sale ou market expect lower expens profil carri
rais ep
ep manag expect rel ep contribut vs fy
lower rel ep contribut note vs fy ep ratio
new ep total meaning declin
prior estim base manag commentari believ much
spend front-load particularli major new product
contribut kick
figur chang model
leerink partner estim note number except ep margin
takeaway investor day
manag would say us price eros stabil note deceler
eros last coupl month believ deceler could continu
gener advair gener advair target action date june met fda
soon call review inform request receiv prior month
respond everi inform request fda issu point believ
outstand scientif issu product manufactur product begun
would readi launch day post approv
gener restasi outstand fda question gener restasi
bridg goal date juli compani believ met bioequival guidelin
note citizen petit file address fda also develop
multi-dos vial formul restasi plan submit anda near futur
gener symbicort gener symbicort demonstr posit pk bioequival
studi product strength well recent complet clinic equival studi
plan file product us
gener once-monthli copaxon once-monthli depot formul copaxon
note partner complet phase studi relaps remit multipl
sclerosi rrm patient switch copaxon phase trial glatiram acet
nave patient rrm plan target submiss
pathway around time-frame
gener premarin disclos addit detail gener premarin program
manag believ symbiotec secur good partner api plan go
api data potenti submiss plan fda
act meloxicam licens investig fast-act meloxicam treatment
prayog lab believ reduc deliveri time drug hour littl
minut manag see product potenti treat chronic
acut pain product earli stage develop ind submiss plan later
year
pdufa date revefenacin novemb appear readi launch
assum get approv revefenacin provid long-act muscarin antagonist lama
option patient moder sever chronic obstruct pulmonari diseas copd
nebul form late unavail patient revefenacin also
number advantag compet product lonhala magnair once-daili dose vs
twice-daili usag rang standard jet nebul vs special eflow
dymista season allerg rhiniti largest individu product acquir meda
transact accord meda ww sale appear
done addit clinic work product look highlight fast onset action
addit approach product includ explor opportun cognit attent
look potenti treatment beyond allerg rhiniti continu garner
approv product around world china phase start-up activ current
europ look drive key global brand dymista continu develop
life cycl manag program like creon influvac biosimilar launch like come
first time near-term launch could come insulin glargin humira
approv herceptin neulasta end plan continu maintain
market leadership posit countri like franc itali expand presenc
countri like germani uk inject arv portfolio remain high prioriti
growth see gener copaxon mani eu countri potenti alon
market brand year over-the-counter manag continu drive growth
product also look portfolio expans potenti acquisit
row opportun driven continu execut key global brand
expans insulin/biosimilar portfolio mani new market row
countri heavili index brand low gener over-the-counter util see
opportun cross-pollin portfolio region continu drive industri
lead arv franchis also look addit diseas state like hepat tuberculosi
malaria base learn arv final look continu drive meda
product exist row market also new market like china brazil
biosimilar neulasta action date us june acknowledg us
opportun roughli half brand sale given onpro compon neulasta
would like impact biosimilar manag expect advisori
committe would held product prior potenti approv
eu submiss biosimilar neulasta herceptin continu progress
ema continu expect approv year-end
morn announc partnership agreement fujifilm kyowa kirin biolog
licens biosimilar humira approv expect continu expect
first wave approv octob note given anticip
develop timelin biosimilar humira partnership biocon unlik permit
launch market format compani move identifi mean get market access
biosimilar botox collabor revanc preclin stage believ
product meet biosimilar threshold due greater similar brand botox
number factor includ drug substanc kda protein strain clostridium
botilinum purif process excipi final product compar toxin
market like dysport xeomin anticip meet fda go
regulatori requir product compani acknowledg demonstr
biosimilar challeng develop assay analyt work
order help adequ demonstr
biosimilar develop includ avastin global clinic studi reach
patient recruit submiss expect novolog top-lin
pk/pd result expect quarter phase studi schedul begin
newli disclos biosimilar program toujeo perjeta part collabor
biocon aranesp collabor ckd pharma
continu target leverag ratio less commit long-
term averag ratio midpoint manag guidanc impli share
buy-back manag also state open busi develop expand
geograph and/or therapeut area reach meda deal brought over-the-counter
franchis deal cold-eez brand would expect continu
growth over-the-counter space
use weight averag ev/ebitda multipl ebitda line
consensu deriv price target per share
gener advair may get approv commerci uptak biosimilar may take longer
anticip growth ou market may slower expect
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
